A Phase II Window Study of Front-line Axitinib Followed by Axitinib and Radiation for Elderly Patients With Glioblastoma Multiforme (GBM)

Inclusion Criteria:

- Newly diagnosed patients with histologically proven glioblastoma multiforme

- Age above 70 years

- Karnofsky score of 50-80

- Adequate organ function as defined by laboratory values

- Life expectancy of >12 weeks

- No evidence of preexisting uncontrolled hypertension as documented by 2 baseline
blood pressure readings taken at least 1 hour apart. The baseline systolic blood
pressure readings must be 140 mm Hg, and the baseline diastolic blood pressure
readings must be 90 mm Hg. Patients whose hypertension is controlled by
antihypertensive therapies are eligible.

Exclusion Criteria:

- Prior treatment with chemotherapy or radiation for glioblastoma multiforme

- Patients with extensive tumor hemorrhage

- Any of the following within the 12 months prior to study drug administration:
myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft,
symptomatic congestive heart failure, cerebrovascular accident or transient ischemic
attack and 6 months for deep vein thrombosis or pulmonary embolism